Radioligand Therapy Market Report 2026

The radioligand therapy market size has grown rapidly in recent years. It will grow from $6.63 billion in 2025 to $7.32 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to limited availability of radioligands, reliance on conventional cancer therapies, growing awareness of targeted therapy benefits, increasing hospital adoption of nuclear medicine techniques, regulatory approvals for early rlt drugs.

The radioligand therapy market size is expected to see rapid growth in the next few years. It will grow to $10.72 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to development of novel alpha and beta emitters, expansion of combined emission therapies, integration with precision oncology, rising clinical trials for neurological and cardiovascular applications, increasing investment in home care and outpatient rlt services. Major trends in the forecast period include increasing adoption of targeted radioligand therapy for oncology, expansion of alpha and beta emitter-based therapies, integration of radioligand therapy with personalized medicine approaches, growth in hospital and research institution-based rlt programs, rising focus on minimizing side effects and enhancing patient outcomes.

The upsurge in cancer incidence is anticipated to boost the radioligand therapy market ahead. Cancer involves runaway abnormal cell proliferation that infiltrates nearby areas and metastasizes. Its rise links to prolonged environmental toxin exposure harming DNA, impairing cells, and spurring rogue growth. Radioligand therapy combats cancer by channeling radiation via receptor-binding ligands to zap tumors precisely, sparing healthy tissue for internal cell kill. For example, in October 2025, the National Health Service (NHS), a UK public health body, recorded 354,820 new cases in 2023 - 972 daily, up 8,605 from 2022. Thus, the climbing cancer incidence is fueling the radioligand therapy market.

Prominent companies in the radioligand therapy market are advancing setups like specialized radioligand therapy facilities to optimize output, quality, and safety in crafting and supplying pinpoint cancer drugs. Radioligand therapy facilities are dedicated hubs managing radioactive agents for focused cancer care, equipped with cutting-edge imaging, shielding, expert staff, and rigorous safeguards. For instance, in January 2024, Novartis AG, a Switzerland pharma leader, automated its massive Indiana radioligand therapy (RLT) plant post-FDA commercial nod. Spanning 70,000 square feet, it's Novartis's biggest, most sophisticated RLT site for swift, high-volume runs with full automation, ramping supply for US and Canada patients.

In December 2023, Eli Lilly and Company, a US pharma giant, snapped up POINT Biopharma Global Inc. for $1.4 billion. This bolsters Eli Lilly's oncology range with top-tier radioligand tech for sharper cancer precision meds. POINT Biopharma Global Inc. is a US firm honing radioligand cancer therapies.

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C‑Ray Therapeutics Inc.

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the radioligand therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the radioligand therapy market by increasing costs of imported radioactive isotopes, ligands, and specialized delivery equipment. Segments like alpha and beta emitter therapies are most affected, particularly in regions like North America and Europe, where imports dominate supply chains. This has led to higher treatment costs and potential delays in therapy availability. On the positive side, tariffs have encouraged local production, investment in domestic radiopharmaceutical facilities, and innovation in cost-efficient RLT solutions.

The radioligand therapy market research report is one of a series of new reports that provides radioligand therapy market statistics, including radioligand therapy industry global market size, regional shares, competitors with a radioligand therapy market share, detailed radioligand therapy market segments, market trends and opportunities, and any further data you may need to thrive in the radioligand therapy industry. This radioligand therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Radioligand therapy (RLT) is an advanced targeted cancer treatment that combines a radioactive isotope with a ligand engineered to bind specifically to cancer cell receptors. Once administered, it locates tumor cells and delivers radiation directly to them, minimizing harm to healthy tissues. This targeted strategy helps reduce side effects and improve outcomes, especially in cancers resistant to conventional therapies.

The main types of radioligands in radioligand therapy include alpha emitters, beta emitters, Auger emitters, and combined emissions. Alpha emitters release high-energy alpha particles over very short distances, typically just a few cell layers, making them highly effective for precise cell destruction. These radioligands target specific molecular markers such as hormone receptors, growth factor receptors, and tumor antigens, and can be administered via intravenous (IV), intramuscular (IM), subcutaneous, or oral routes. Radioligand therapy is applied in oncological, cardiovascular, neurological, and infectious disease treatments, and is utilized by hospitals, diagnostic laboratories, research institutions, and home care settings.

The radioligand therapy market consists of revenues earned by entities by providing services such as targeted treatment services, diagnostic imaging, and clinical and infrastructure services. The market value includes the value of related goods sold by the service provider or included within the service offering. The radioligand therapy market also includes sales of somatostatin receptor ligands, radiolabeled bombesin analogs, radiolabeled monoclonal antibodies, and prostate-specific membrane antigen (PSMA)-targeted ligands. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.